Login to Your Account



Celldex kicks off CDX-301 pilot, hoping to lower transplant risk

By Michael Fitzhugh
Staff Writer

Thursday, September 25, 2014
Celldex Therapeutics Inc. is initiating a pilot study testing the ability of CDX-301, a recombinant FMS-like tyrosine kinase 3 (Flt3) ligand it licensed from Amgen Inc. in March 2009, to mobilize and improve transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription